Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EPS (Weighted Average and Diluted) (2020 - 2025)

TransMedics (TMDX) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at $2.59 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 1195.0% year-over-year to $2.59; the TTM value through Dec 2025 reached $4.87, up 382.18%, while the annual FY2025 figure was $4.87, 382.18% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $2.59 in Q4 2025 per TMDX's latest filing, up from $0.66 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.59 in Q4 2025 and bottomed at -$0.78 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.11, with a median of -$0.06 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 212.0% in 2023, then skyrocketed 1266.67% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.45 in 2021, then soared by 55.56% to -$0.2 in 2022, then surged by 160.0% to $0.12 in 2023, then surged by 66.67% to $0.2 in 2024, then skyrocketed by 1195.0% to $2.59 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $2.59 in Q4 2025, $0.66 in Q3 2025, and $0.92 in Q2 2025.